Jane Street’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

Jane Street’s Portfolio THNR Stock Details THNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$450K	Buy	+17,514	New	+$431K	﹤0.01%	8269
2025 Q4	–	Sell	-23,704	Closed	-$555K	–	12655
2025 Q3	$555K	Buy	+23,704	New	+$545K	﹤0.01%	7630
2025 Q2	–	Sell	-24,891	Closed	-$536K	–	11167
2025 Q1	$536K	Buy	24,891 +1,215	+5%	+$27.6K	﹤0.01%	6733
2024 Q4	$534K	Buy	23,676 +9,123	+63%	+$225K	﹤0.01%	6644
2024 Q3	$390K	Sell	14,553 -6,656	-31%	-$179K	﹤0.01%	7611
2024 Q2	$553K	Buy	+21,209	New	+$545K	﹤0.01%	6860

Other funds holding THNR

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

GFA

Godfrey Financial Associates Glenmont, New York $131M AUM

Jane Street's THNR Position: Q2 2026 in Review

Jane Street opened a new position in Amplify Weight Loss Drug & Treatment ETF (THNR) in Q2 2026: 17,514 shares worth $450K. The stake represents ﹤0.01% of the portfolio and ranks #8269 among its holdings. This is a return to the name: Jane Street previously reported a position in THNR as recently as Q3 2025.

Jane Street first reported a position in THNR in Q2 2024 and has held it in 6 quarters since. The position peaked at $555K in Q3 2025. 4 funds tracked by Wall St. Rank hold THNR as of Q2 2026.

Jane Street held 17,514 shares of Amplify Weight Loss Drug & Treatment ETF worth $450K as of Q2 2026.
Amplify Weight Loss Drug & Treatment ETF was a new Jane Street position in Q2 2026.
Amplify Weight Loss Drug & Treatment ETF made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8269 holding.
Jane Street first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q2 2024 and has held it in 6 quarters since.
Jane Street's Amplify Weight Loss Drug & Treatment ETF position peaked at $555K in Q3 2025.
4 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.